RenovoRx, Inc. (RNXT) News
Follow RenovoRx, Inc. (RNXT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
RenovoRx raises 2026 revenue outlook to $3.75 million-$4.25 million
EARNINGS | Nov 11, 2026, 07:29 PM UTC
M
RenovoRx Reports Third-Quarter 2026 Revenue of $1.07 Million
Revenue rose from $266,000 a year earlier. RenovoRx maintained 2026 revenue guidance of $3.75 million to $4.25 million and said cash resources should fund operations into the second half of 2027. Active cancer center cus
EQUITY | Nov 06, 2026, 02:05 PM UTC
M
RenovoRx reports quarterly results for period ended September 30
A machine-generated LSEG summary reports RenovoRx results for the quarter ended September 30; the supplied text contains no figures.
EQUITY | Nov 05, 2026, 11:28 PM UTC
H
RNXT: RenovoCath's commercial and clinical momentum accelerates with strong survival data and expanding adoption
RenovoCath's targeted drug delivery system is gaining rapid commercial traction, now in 21 centers with plans to exceed 35 by year-end. Interim phase III data show a six-month survival benefit and 65% reduction in toxici
EARNINGS | Sep 14, 2026, 08:06 PM UTC
H
RNXT: RenovoCath's device shows strong adoption, survival benefit, and reduced toxicities in pancreatic cancer
RenovoCath's proprietary delivery system is driving rapid commercial adoption, with 21 centers active and a $400 million market opportunity. Interim phase III data show a 6-month survival benefit and 65% reduction in tox
EARNINGS | Sep 14, 2026, 07:42 PM UTC
L
RNXT jumps to 52-week high amid biotech strength
RNXT shares rose to a 52-week high, +15%. Other biotech names cited: EOLS, CRNX, APGE.
EQUITY | Sep 01, 2026, 08:01 AM UTC
L
Ascendiant Capital raises RenovoRx price target to $14.50
Ascendiant Capital raised its RenovoRx price target to $14.50/share from $14.00/share.
EQUITY | Aug 28, 2026, 11:00 AM UTC
L
RenovoRx RNXT highlights peer-reviewed PK/PD data for TAMP targeting
RenovoRx (RNXT) highlights a peer-reviewed publication presenting pharmacokinetic and pharmacodynamic (PK/PD) data supporting its TAMP™ targeted drug-delivery platform in locally advanced pancreatic cancer.
EQUITY | Aug 25, 2026, 12:30 PM UTC
M
RenovoRx regains Nasdaq minimum bid price compliance
RenovoRx says it has regained compliance with Nasdaq’s minimum bid price requirement for RNXT.
REGULATION | Aug 21, 2026, 12:30 PM UTC
M
RenovoRx gets U.S. patent allowance notice for RenovoCath® catheter
RenovoRx (RNXT) receives a notice of allowance for a new U.S. patent covering RenovoCath®, an advanced dual-occlusion catheter for targeted therapeutic drug-delivery in cancer treatment.
REGULATION | Aug 20, 2026, 12:31 PM UTC
L
RenovoRx Raises FY2026 Sales Guidance
RenovoRx raises FY2026 sales outlook to $3.750M-$4.250M
EARNINGS | Aug 12, 2026, 08:15 PM UTC
L
RNXT Reports Record Q2 2026 Results
RNXT reports record second quarter 2026 results with 61% sequential revenue growth
EARNINGS | Aug 12, 2026, 08:05 PM UTC
M
RenovoRx Expands RenovoCath Use To Solid Tumors
RenovoRx expands use of RenovoCath to solid tumors
EQUITY | Aug 06, 2026, 12:31 PM UTC
L
RNXT - RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET - Click
RNXT - RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
EARNINGS | Jul 29, 2026, 12:30 PM UTC